Azithromycin drug interactions.
Pre clinical work in vivo and in vitro have suggested that azithromycin has a low potential for significant drug interactions. Clinical studies conducted thus far have generated results in accordance with the preclinical science [6]. Direct comparisons with the most modern macrolides have been published and evidence suggests that azithromycin is likely to be associated with fewer significant drug interactions. However, as a final point, I wish to point out that proof of an absolute negative is not possible and therefore in any patient, on multiple medication with adverse findings, a drug interaction should be considered as part of the differential diagnosis.
Felstead
S
S
Clinical and Safety Regulatory Affairs, PFYZER Central Research, Sandwich, UK.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D017963:Azithromycin / Q000494:pharmacology*; D002220:Carbamazepine / Q000494:pharmacology*; D004077:Digoxin / Q000494:pharmacology; D004347:Drug Interactions; D004878:Ergotamine / Q000494:pharmacology; D066298:In Vitro Techniques; D008775:Methylprednisolone / Q000494:pharmacology*; D011517:Prothrombin Time; D016593:Terfenadine / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology*; D014859:Warfarin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D002220:Carbamazepine; D014859:Warfarin; D004077:Digoxin; D016593:Terfenadine; D017963:Azithromycin; D013806:Theophylline; D004878:Ergotamine; D008775:Methylprednisolone